PAM Pathway
Overactivation of the PAM (PI3K/AKT/mTOR) pathway plays a key role in the progression of a wide variety of human cancers.
REVTORPYK™ (gedatolisib) is FDA-approved as a 2nd-line treatment for HR+/HER2-PIK3CA wild-type advanced breast cancer.
Our Pipeline
We are evaluating gedatolisib across a range of solid tumors to improve patient outcomes.
Clinical Trials
We have multiple ongoing clinical trials for gedatolisib as a potential treatment for breast and prostate cancer.
Recent News
August 26, 2026
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
August 13, 2026
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
August 6, 2026
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call